Evotec loses research chief. Evotec stock falls 2.03 percent

Published on 10/07/2026 at 14:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached EUR 143.48 million in the second quarter, versus EUR 171.24 million. Evotec stock costs EUR 2.89 on October 7, 2026 after EUR 2.95.

Flatlay mit Aktienzertifikat, ISIN-Karte, Molekülmodell, Pipette und Petrischale auf weißem Grund — Flatlay-Arrangement mit Aktienzertifikat und ISIN-Karte DE0005664809 visualisiert die Aktie von Evotec SE als Biotech-Investment, Illustration mit AI erstellt.

Evotec stock (ISIN DE0005664809) was trading at EUR 2.89 at Lang & Schwarz on October 7, 2026 at 2:44 p.m. CEST, down 2.03 percent versus the prior close of EUR 2.95. As FinanzNachrichten.de reported on October 3, 2026, research chief Cord Dohrmann left the company on September 30, 2026, as Evotec continues its Horizon restructuring.

Leadership change meets weak revenue

The management change arrives after a difficult second quarter. According to finanzen.ch on October 7, 2026, Evotec reported revenue of EUR 143.48 million for the quarter ended June 30, 2026, down 16.21 percent from EUR 171.24 million a year earlier.

The same report lists a loss per share of EUR 0.26 for the second quarter, compared with EUR 0.24 in the prior-year quarter. Finance data for Evotec show net income of minus EUR 46.65 million and operating profit of minus EUR 113.27 million for the same period.

Horizon must convert savings into growth

Evotec's full-year outlook is now centered on revenue of EUR 570 million to EUR 610 million in fiscal 2026. The company previously targeted EUR 700 million to EUR 780 million, making the revised range a material reset for investors tracking the turnaround.

The operating picture is also under pressure. Adjusted EBITDA for the first half of 2026 was minus EUR 42.70 million, while first-half revenue totaled EUR 300.10 million, according to Börse Express on September 27, 2026.

Horizon is intended to improve efficiency, but the numbers show why execution matters more than the restructuring label itself. Revenue in the second quarter was EUR 27.76 million below the comparable prior-year figure, while the operating loss remained substantially larger than revenue growth could absorb.

Analyst target remains above the price

Berenberg kept its Hold rating and a EUR 3.60 price target after a discussion with Evotec Chief Executive Christian Wojczewski, according to finanzen.ch on September 25, 2026. The cited original study was published on September 24, 2026.

At EUR 2.89, the Lang & Schwarz price is EUR 0.71 below that target, or 19.72 percent below it. The gap reflects the market's demand for clearer evidence that the Horizon program can stabilize revenue and narrow losses.

Evotec stock tests its September low

Evotec stock was trading at EUR 2.89 at Lang & Schwarz on October 7, 2026 at 2:44 p.m. CEST, down 2.03 percent versus the prior close of EUR 2.95. The Xetra listing is part of the MDAX, and a September 25, 2026 low of EUR 2.71 places the latest Lang & Schwarz price EUR 0.18 above that level.

The further course of trading is shown by the continuously updated real-time quote of Evotec stock.